AstraZeneca's Truqap and Faslodex combo receives approval in EU [Yahoo! Finance]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
This marks a significant development for patients with oestrogen receptor (ER)-positive, HER2-negative breast cancer, who have experienced disease progression after endocrine-based therapy. The European Commission's decision follows a favourable recommendation from the Committee for Medicinal Products for Human Use (CHMP). It is underpinned by results from the Phase III CAPItello-291 trial, which demonstrated a 50% reduction in the risk of disease progression or death when Truqap was used in combination with Faslodex, compared to Faslodex with placebo. The double-blinded and randomised trial, which enrolled 708 patients, showcased a median progression-free survival of 7.3 months for the combination therapy versus 3.1 months for the placebo group. The safety profile observed was consistent with previous studies of the combination. It focused on the efficacy of Truqap in conjunction with Faslodex against a placebo plus Faslodex regimen. The trial targeted a specific patient g
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer [Yahoo! Finance]Yahoo! Finance
- AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer [Yahoo! Finance]Yahoo! Finance
- Impact and implications of the $35 monthly price cap on asthma inhalers [Yahoo! Finance]Yahoo! Finance
- China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients [Yahoo! Finance]Yahoo! Finance
- Corporate Reputation of Pharma in Canada, 2023/2024: The Views of 100 Canadian Patient Groups - Fair Pricing Policies, Transparency of Pricing, and Engaging Patients in R&D Among the Lowest-Scoring Indicators [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 6/26/24 - Form 11-K
- 6/25/24 - Form 6-K
- 6/25/24 - Form 6-K
- AZN's page on the SEC website